Daily Ards Research Analysis
Three studies advance ARDS-related science across mechanics, translational platforms, and biomarkers. A 3D multiscale lung model implicates atelectasis-driven heterogeneous ventilation as a source of microvolutrauma; an organ-on-chip placenta–fetal lung platform refines antenatal corticosteroid dosing; and plasma arginase-1 emerges as a prognostic biomarker in sepsis-induced ARDS.
Summary
Three studies advance ARDS-related science across mechanics, translational platforms, and biomarkers. A 3D multiscale lung model implicates atelectasis-driven heterogeneous ventilation as a source of microvolutrauma; an organ-on-chip placenta–fetal lung platform refines antenatal corticosteroid dosing; and plasma arginase-1 emerges as a prognostic biomarker in sepsis-induced ARDS.
Research Themes
- Mechanobiology of heterogeneous ventilation and ventilator-induced lung injury
- Organs-on-chips for perinatal respiratory therapeutics and dosing
- Inflammation and biomarkers in sepsis-induced ARDS
Selected Articles
1. Understanding the impact of antenatal corticosteroids via placenta and fetal lung microphysiological analysis platform (MAP) on a chip.
A placenta–fetal lung organ-on-chip was engineered to quantify corticosteroid transport and effect on fetal pneumocyte surfactant production. Concentrations above 5 mM impaired trophoblast viability without increasing surfactant output, highlighting a therapeutic window for antenatal corticosteroids.
Impact: Introduces a multi-compartment microphysiological platform that mechanistically links placental transport to fetal lung response, enabling rational dosing strategies. This bridges a critical translational gap in antenatal corticosteroid therapy.
Clinical Implications: Suggests avoiding excessive dosing that may injure trophoblasts while failing to boost surfactant, supporting dose optimization of antenatal corticosteroids to balance efficacy and placental safety.
Key Findings
- Developed a placenta–fetal lung MAP integrating trophoblast, capillary, and pneumocyte compartments.
- Corticosteroid concentrations >5 mM reduced trophoblast viability without increasing pneumocyte surfactant production.
- Demonstrated a platform to map transport–response relationships to guide antenatal corticosteroid dosing.
Methodological Strengths
- Organ-on-chip with physiologically relevant multi-compartment architecture.
- Systematic dose–type–duration assessment linking placental transport to fetal lung function readouts.
Limitations
- In vitro platform without in vivo validation or clinical correlation.
- Concentration ranges and exposure conditions may not directly map to in vivo pharmacokinetics.
Future Directions: Validate transport and efficacy thresholds against clinical dosing and outcomes; integrate maternal/fetal pharmacokinetics to derive clinically actionable dosing regimens.
Antenatal corticosteroids are recommended for preterm births to enhance lung maturity; however, the guidelines are based on limited studies. Here, we present a placenta-fetal lung microphysiological analysis platform (MAP) to study how corticosteroids promote fetal lung maturation and determine their optimal concentration with minimal side effects. We create trophoblast-capillary-pneumocyte MAP on chips to analyze the transport of corticosteroids from mother to fetus through the placenta. We assessed surfactant production from the pneumocyte after exposure to different concentrations, types, and durations of corticosteroids in the trophoblast layer. We found the concentrations of corticosteroids over 5 mM reduced trophoblast viability and did not increase the surfactant production from pneumocytes. Our research on placenta-fetal lung MAP provides insight into how corticosteroids improve the production of surfactant from immature pneumocytes as they transition from the placenta and suggests that determining the appropriate dosage of corticosteroids to maximize effectiveness while preventing damage to trophoblasts is crucial.
2. Predictions of Atelectasis-Induced Microvolutrauma: A Key Pathway to Ventilator-Induced Lung Injury.
A 3D multiscale model shows that atelectasis-driven heterogeneity concentrates tensile stress in collagen fibers of adjacent parenchyma, providing a mechanistic link to microvolutrauma and VILI. A simplified periacinar pressure model offers a tractable framework to study these interactions.
Impact: Provides a mechanistic basis for how derecruitment and heterogeneous ventilation propagate injury to nominally healthy lung regions, informing protective ventilation strategies.
Clinical Implications: Supports ventilation strategies that minimize derecruitment and regional heterogeneity (e.g., appropriate PEEP, careful recruitment), potentially reducing VILI in ARDS.
Key Findings
- A full 3D multiscale lung parenchyma model integrating elastin and collagen mechanics predicts stress hotspots.
- Atelectasis boundaries produce marked stress concentrations in adjacent normal parenchyma under heterogeneous ventilation.
- A reduced-dimension periacinar pressure model captures key mechanical interactions with lower complexity.
Methodological Strengths
- Multiscale integration of extracellular matrix fiber mechanics at the alveolar level.
- Complementary reduced-order model enabling tractable analysis and hypothesis generation.
Limitations
- Purely computational with no experimental or in vivo validation presented.
- Assumptions about tissue properties and boundary conditions may limit generalizability.
Future Directions: Validate predictions with imaging/functional data (e.g., EIT, CT strain mapping); incorporate patient-specific parameters to personalize ventilatory strategies.
This study presents a full three-dimensional multiscale computational model of lung parenchyma to investigate how heterogeneous alveolar ventilation generates regions of high stress. The model integrates elastin and collagen fiber mechanics at the alveolar level to capture microstructural interactions. Simulations of nonuniform alveolar pressure, particularly in the presence of atelectasis (collapsed lung regions), reveal significant localized distortions in adjacent normal parenchyma, especially along the atelectatic boundary. Results demonstrate that heterogeneous ventilation induces substantial stress concentrations in surrounding healthy tissue, which may contribute to lung injury and disease progression in acute respiratory distress syndrome (ARDS) and ventilator-induced lung injury (VILI). A reduced-dimension periacinar pressure model is introduced to provide a simplified yet effective framework for analyzing these mechanical interactions. Notably, the model shows that even under seemingly normal transmural pressures, alveolar collagen fibers near atelectatic regions experience extreme tensile stresses, which could be misinterpreted as microvolutrauma despite originating from atelectasis. These findings underscore the critical role of heterogeneous ventilation in driving injurious mechanical forces within the lung, highlighting the need for ventilation strategies that minimize airway closure or alveolar derecruitment.
3. Predictive efficacy of plasma arginase 1 as a novel biomarker for mechanical ventilated patients with sepsis induced acute respiratory distress syndrome: a prospective cohort study.
In 46 ventilated ARDS patients, plasma ARG1 was elevated in sepsis-ARDS, correlated with severity indices, and predicted 28-day mortality (AUC 0.80). Neutrophils were identified as a key ARG1 source, supporting its pathobiological relevance.
Impact: Proposes ARG1 as a practical, mechanistically grounded biomarker for risk stratification in sepsis-ARDS, with additive value to SOFA.
Clinical Implications: Early ARG1 measurement may identify high-risk sepsis-ARDS patients for intensified monitoring, tailored ventilation, and trial enrollment; combining ARG1 with SOFA improves prognostic discrimination.
Key Findings
- Plasma ARG1 levels were higher in sepsis-ARDS than in non-sepsis ARDS.
- ARG1 correlated with APACHE II, SOFA, IL-6, lactate, and inversely with PaO2/FiO2.
- ARG1 predicted 28-day mortality in sepsis-ARDS (AUC 0.80) and improved performance when combined with SOFA.
- Neutrophils showed high ARG1 production with increased degranulation by flow cytometry.
Methodological Strengths
- Prospective cohort with predefined outcomes and biomarker quantification by ELISA.
- Multimodal validation including clinical correlations and cellular source by flow cytometry.
Limitations
- Single-center small sample size (n=46) limits generalizability and precision.
- Lack of external validation and limited adjustment for potential confounders.
Future Directions: Validate ARG1 thresholds in multicenter cohorts; test integration into multimarker panels and decision-support tools for sepsis-ARDS.
While acute respiratory distress syndrome (ARDS) is the highest mortality with the worse outcomes among other causes of ARDS, a few studies focused on the risk identification of sepsis-ARDS. Here, this study determined the levels of plasma arginase 1 (ARG1) to apply as a novel biomarker for sepsis-ARDS. A total of 46 endotracheal intubated patients with ARDS categorized as sepsis-ARDS (n = 28) and non-sepsis ARDS (n = 18) were enrolled. The clinical outcomes were obtained prospectively and ARG1 level was determined by ELISA. Plasma ARG1 in sepsis-ARDS was higher than non-sepsis ARDS and correlated with ARDS severity, including APACHE II score, SOFA score, interleukin-6, lactate, and the reduced PaO2/FiO2 ratio. Additionally, the higher plasma ARG1 in sepsis-ARDS indicated the higher mortality and the longer duration of ventilator use. There was a non-significant correlation in patients with non-sepsis ARDS. The area under the curves (AUC) in a receiver operating characteristic (ROC) curve of ARG1 for the prediction of 28-days mortality and ventilator free day in sepsis-ARDS were 0.80 and 0.67, respectively, while AUC to diagnose sepsis-ARDS was 0.72, All the performances were improved when combined the ARG1 levels with SOFA score. Moreover, the relationship between plasma ARG1 and neutrophils was demonstrated. Flow cytometry demonstrated a high level of neutrophil ARG1 production with high degranulation levels, supporting the role of neutrophils in ARG1 production during sepsis-ARDS. In conclusion, the plasma ARG1 levels may be a potential marker for predicting the worsen outcomes of sepsis-ARDS. Early detection of plasma ARG1 could help clinicians to manage sepsis-ARDS.